Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Netherlands Gives Funding Nod To CGRP Inhibitors For Chronic Migraines

Executive Summary

The Dutch health technology appraisal body, ZIN, said Novartis’ Aimovig should be reimbursed for the treatment of chronic migraine after initially advising against it.

You may also be interested in...

UK Funding Nod For Novartis Migraine Drug After Bumpy Ride

Following two previous rejections by the UK’s health technology assessment body and an appeal, Aimovig is now available on the National Health Service for preventing migraine.

Relief For Migraine as England’s NICE Reverses Ajovy Knockback

The latest decision by the health technology assessment body means up to 10,000 people will be able to receive Teva’s drug on the National Health Service. Ajovy is the first anti-CGRP migraine therapy recommended by NICE, whose decision will also be of interest to CGRP inhibitor rivals including Novartis, Lilly and Lundbeck.

Do Fast Track Regulatory Pathways Mean Quicker Reimbursement For Gene Therapies?

The norms on securing market access are being rewritten for cell and gene therapies.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts